In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CuraGen Corp.

Division of Celldex Therapeutics Inc.
www.curagen.com

Latest From CuraGen Corp.

Appointments: Celgene's COO Departs, New CEOs At Abeona, Kleo and Corvidia And Board Changes

This week's company moves include the sudden departure of Celgene's COO, new CEOs at Abeona Therapeutics, Kleo Pharmaceuticals and Corvidia Therapeutics, while board appointments have been made at Neurocentrx, Hemogenyx Pharmaceuticals, Emergex Vaccines and Rezolute Inc.

Appointments BioPharmaceutical

Takeda strengthens cancer focus with Mersana ADC deal

Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals.

Infectious Diseases Cancer

Qiagen's Intelligent Bio-Systems buy seen as wise jump into genome sequencing

Dutch molecular diagnostics specialist Qiagen has become the latest firm to enter the next-generation genome sequencing foray, having revealed that it has acquired privately-held Intelligent Bio-Systems and hopes to launch its first next-generation sequencing (NGS) solution next year.

Cancer

Roche's improved bid for Illumina is a step forward

Two months after launching its hostile takeover bid of Illumina and having made little progress, Roche has increased its offer by 15%, to $51 per share, bringing the total transaction value to $6.7 billion. However, this still may not be enough for the Swiss drugs and diagnostics giant to bag the gene sequencing firm, the stock of which analysts have previously said could be worth around $60 per share.

See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celldex Therapeutics Inc.
  • Senior Management
  • Timothy Shannon, MD, Pres. & CEO
    Sean Cassidy, VP, CFO
  • Contact Info
  • CuraGen Corp.
    Phone: (203) 481-1104
    322 East Main St.
    Branford, CT 06405
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register